BPC-157 , also known as Body Protection Compound-157 , is a synthetic peptide derived from gastric juice
Crystal accumulation in cystinosis was first described by Abderhalden in 1903 and the glucose wasting of cystinosis was recognized in 1931 by Dr
CPT1A and metabolic diseases Patients with metabolic syndrome, obesity, and type 2 diabetes frequently have non-alcoholic fatty liver disease, hypertriglyceridemia, and other lipid metabolism abnormalities, which can be somewhat improved by increasing CPT1A expression ( CPT1A in vascular diseases Metabolism of endothelial cell depends on FAO to resist oxidative stress in the development of blood vessels, and CPT1A plays a crucial role in this process, offering a new potential target for the treatment of vascular-related diseases (Rohlenova et al., 2018)
Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation
If for any reason, the physician does not approve, you will be fully refunded.
